Company Overview and News

 
EXEL INDUSTRIES : Actions et droits de vote au 30/09/2018

2018-10-05 globenewswire
EXEL Industries Société Anonyme au capital de 16 969 750 € Siège Social : 54, rue Marcel Paul 51206 Epernay Cedex RCS Reims n° B 095 550 356
EXE

 
EXEL INDUSTRIES :shares and voting rights 30.09.2018

2018-10-05 globenewswire
EXEL Industries A French public limited company (Société Anonyme) with a share capital of €16,969,750 Registered office: 54, rue Marcel Paul 51206 Epernay Cedex- France Reims Companies Register (RCS): No. B 095 550 356
EXE

 
EXEL Industries éligible au PEA - PME

2018-07-26 globenewswire
EXEL Industries - spécialiste des techniques de pulvérisation pour l'agriculture et l'industrie, leader mondial des arracheuses de betteraves - confirme respecter les critères d'éligibilité au PEA-PME indiqués par le décret d'application en date du 4 mars 2014 (décret n°2014-283).
EXE

 
EXEL INDUSTRIES :BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE CONTRACTE AVEC LA SOCIETE DE BOURSE GILBERT DUPONT

2018-07-26 globenewswire
Société Anonyme au capital de 16 969 750 € Siège Social : 54, rue Marcel Paul 51206 Epernay Cedex RCS Epernay n° B 095 550 356
EXE

14
EXEL INDUSTRIES :Third quarter 2017-2018 revenue Slight growth over the quarter at constant exchange rates

2018-07-19 globenewswire
(*) Amounts at constant exchange rates are calculated by converting the amounts for the current year using the average monthly exchange rate for the previous year
GM EXE

14
EXEL INDUSTRIES :Chiffre d'affaires 3ème trimestre 2017-2018 Un trimestre en légère croissance à taux de change constants

2018-07-19 globenewswire
(*) Les montants à taux de change constants sont calculés en convertissant les montants de l'année en cours aux taux de change moyens mensuels de l'année précédente
GM EXE

 
EXEL INDUSTRIES :Résultats Semestriels 2017-2018 : un résultat semestriel moins positif que l'année dernière

2018-05-31 globenewswire
Compte tenu de la saisonnalité de nos activités, le premier semestre de l'exercice fiscal ne représente qu'une faible part de nos résultats annuels. L'année dernière, il représentait 40% du chiffre d'affaires et 22% du résultat opérationnel courant annuel.
EXE

 
EXEL INDUSTRIES :2017-2018 first-half results : first-half results less positive than last year's

2018-05-31 globenewswire
Given the seasonal nature of our activities, the first half of the fiscal year represents a relatively small percentage of full-year results: in the 2016-2017 fiscal year, this accounted for 40% of FY sales and 22% of FY current operating income.
EXE

 
EXEL INDUSTRIES : Chiffre d'affaires 2ème trimestre 2017-2018 Un trimestre faible dans un contexte monétaire défavorable

2018-04-19 globenewswire
(*) Les montants à taux de change constants sont calculés en convertissant les montants de l'année en cours aux taux de change moyens mensuels de l'année précédente
EXE

 
EXEL INDUSTRIES : Second-quarter sales 2017-2018 A weak quarter in an unfavorable currency context

2018-04-19 globenewswire
*Constant currency basis: constant currency figures are calculated by translating the current year figures at prior year monthly average exchange rates.
EXE

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to EPA:EXE / EXEL INDUSTRIES on message board site Silicon Investor.

Exelixis, Inc. (EXEL) Exelixis, Inc. (EXEL) Exelixis, Inc. (EXEL) American MultiPlexer (AMUT) -- Cheap Now, But for How Long American MultiPlexer (AMUT) -- Cheap Now, But for How Long American MultiPlexer (AMUT) -- Cheap Now, But for How Long
EXETER RESOURCE CORPORATION (XRC:TSX-V) (EXRCF-OTC) EXETER RESOURCE CORPORATION (XRC:TSX-V) (EXRCF-OTC) EXETER RESOURCE CORPORATION (XRC:TSX-V) (EXRCF-OTC) (SWY.TO) Executes Mandate Letter With Lead Arrangers for Ren (SWY.TO) Executes Mandate Letter With Lead Arrangers for Ren (SWY.TO) Executes Mandate Letter With Lead Arrangers for Ren
Executive Compensation Executive Compensation Executive Compensation NEXEN--NXY on the TSE NEXEN--NXY on the TSE NEXEN--NXY on the TSE
PRXL - Parexel International PRXL - Parexel International PRXL - Parexel International Fidelity Execution Problems Fidelity Execution Problems Fidelity Execution Problems
Complacency Indexes Complacency Indexes Complacency Indexes LXNT: Lexent, Inc. LXNT: Lexent, Inc. LXNT: Lexent, Inc.